{"id":"W3178904653","doi":"10.1002/hon.2898","title":"Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"Novartis Pharma; Celgene","keywords":"Ruxolitinib; International Prognostic Scoring System; Medicine; Myelofibrosis; Internal medicine; Adverse effect; Anemia; Clinical endpoint; Janus kinase inhibitor; Gastroenterology; Surgery; Clinical trial; Bone marrow; Janus kinase; Myelodysplastic syndromes","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003333071,0.0002563491,0.001094641,0.0001793632,0.00006420617,0.00003564326,0.0001402191,0.0001261934,0.00002551449],"category_scores_gemma":[0.0005372397,0.0001525357,0.00004579289,0.0002523076,0.0002506773,0.00009395486,0.0003491083,0.0003664008,0.000002002063],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002900522,"about_ca_system_score_gemma":0.0001096842,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007621128,"about_ca_topic_score_gemma":0.0006983683,"domain_scores_codex":[0.9976913,0.0003983811,0.0008050645,0.0005417803,0.0002585332,0.0003049927],"domain_scores_gemma":[0.9978818,0.001330066,0.0003062559,0.0002026297,0.0001518396,0.0001273943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003259434,0.006420154,0.9823825,0.0002042282,0.0001914593,0.0006562304,0.001097712,0.00001409887,0.00001068837,0.0003277666,0.000001895579,0.005433885],"study_design_scores_gemma":[0.02815047,0.003183544,0.9644592,0.0009275122,0.0001562379,0.0001165923,0.001678079,0.00102988,0.0001401121,0.0000211372,0.000005947181,0.0001313149],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976351,0.0001603395,0.00004616459,0.0002344565,0.0001740893,0.001561266,0.00002087112,0.00002553055,0.0001422213],"genre_scores_gemma":[0.9992641,0.0001515918,0.0001510159,0.00005278561,0.000021991,0.0002742082,0.00006582587,0.00001489468,0.000003597449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02489103,"threshold_uncertainty_score":0.6220227,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02074939354465334,"score_gpt":0.3252005367022574,"score_spread":0.3044511431576041,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}